OmniAb, Inc (OABI) Fair Value & Analysis
Healthcare · US · Market cap $339M
OmniAb, Inc
OABI · US
Fair value as of: Jul 24, 2026
From 1 valuation models · updated yesterday
Share price −11.0% over the past month.
Price vs Fair Value (12 months)
12‑month range $1.36 – $2.72 · fair‑value band $0.1190 – $0.2295 · the $2.03 price screens above the $0.1870 fair value. As of Jul 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
OmniAb, Inc (OABI) currently trades at $2.03, while our model-based Fair Value estimate is $0.1870, implying the stock looks roughly 90.8% overvalued today. We read business quality at 32/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at $28.9M. Revenue grew 247.3% year over year. It earns a return on equity of -20.3%. The balance sheet holds a net cash position of $5.2M. Fundamentals as of Jul 24, 2026
Our scenario range runs from $0.1190 (bear case) to $0.2295 (bull case); at $2.03, the current price sits above that range. The share trades about 27% below its 52-week high and 56% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -27% fair-value upside, at -91%, OABI screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 24, 2026. TTM = trailing twelve months.
About the company
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics. The company offers animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences; OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
OmniAb, Inc reported revenue of $18.7M in FY2025 versus $34.7M in FY2021, a compound −14.4%/yr. Reported net income was −$64.8M in FY2025.
Is OABI fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | 7,746 MXN | 4,803 MXN | -38% |
| Regeneron Pharmaceuticals, Inc REGN34 | R$52.04 | R$46.95 | -10% |
| argenx SE ARGNF | $935.38 | $382.64 | -59% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,011,109 KRW | +1% |
| CSL Limited CSL | A$102.95 | A$126.79 | +23% |
| Celltrion, Inc 068270 | 183,600 KRW | 76,325 KRW | -58% |
| BioNTech SE B1NT34 | R$29.19 | R$21.38 | -27% |
| WuXi Biologics (Cayman) Inc 2269 | HK$32.74 | HK$24.99 | -24% |
| Innovent Biologics, Inc 1801 | HK$85.35 | HK$21.13 | -75% |
| Genmab A/S GMAB | kr 1,656 | kr 524.15 | -68% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is OmniAb, Inc (OABI) undervalued?
What is the fair value of OABI?
What is the quality score of OABI?
What is the revenue of OmniAb, Inc (OABI)?
What is the net profit margin of OABI?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full OmniAb, Inc analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.